# oHCM FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/ohcm

> No upcoming FDA catalysts in oHCM; 2 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### What are the upcoming FDA decisions for oHCM?

No upcoming FDA catalysts in oHCM; 2 past events are recorded. SEC Form 10-K: "We have submitted an NDA to FDA for aficamten for the treatment of oHCM, which was accepted for filing with a PDUFA target action date of September 26, 2025." [Calendar and source filings](https://sec-api.dev/indications/ohcm)

Source: SEC Form 10-K, accession 0000950170-25-029206, https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm (retrieved 2026-11-12). Last confirmed 2025-11-05. Cite: https://sec-api.dev/indications/ohcm#answer

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| September 19, 2024 | [EDG-7500 topline data readout](https://sec-api.dev/pdufa/edg-7500) | EWTX | oHCM | completed, positive | "In EDG-7500, on September 19, 2024, we announced positive topline data from the Phase 1 trial of EDG-7500 in healthy subjects and the Part A single-dose arm of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM, on April 2, 2025, we announced positive topline results from Part B and Part C of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM, and on June 16, 2026, we announced positive topline results from Part D of the Phase 2 multipart CIRRUS-HCM trial in patients with oHCM and nHCM." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1710072/000110465926122653/ewtx-20260930x10q.htm)) |
| September 26, 2025 | [MYQORZO® (aficamten) PDUFA date](https://sec-api.dev/pdufa/aficamten) | CYTK | oHCM | delayed | "We have submitted an NDA to FDA for aficamten for the treatment of oHCM, which was accepted for filing with a PDUFA target action date of September 26, 2025." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1061983/000095017025029206/cytk-20241231.htm)) |

## Drugs

- [EDG-7500](https://sec-api.dev/pdufa/edg-7500) (EWTX)
- [MYQORZO® (aficamten)](https://sec-api.dev/pdufa/aficamten) (CYTK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/ohcm.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "oHCM FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/ohcm

```bibtex
@misc{secapidev_indications_ohcm_20261116,
  title        = {oHCM FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/ohcm}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_ohcm_20261116","title":"oHCM FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/ohcm","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
